OP
PRTK

Omni Partners’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Omni Partners’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-154,564
Closed -$2.01M – 31
2018
Q1 		$2.01M Buy
+154,564
New +$2.3M 0.28% 22
2017
Q4 		– Sell
-147,700
Closed -$3.71M – 27
2017
Q3 		$3.71M Buy
+147,700
New +$3.44M 0.47% 21

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Omni Partners's PRTK Position: Q2 2018 in Review

Omni Partners sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2018, closing a stake of 154,564 shares — an estimated $2.01M sold.

Omni Partners first reported a position in PRTK in Q3 2017 and held it in 2 quarters. The position peaked at $3.71M in Q3 2017. 110 funds tracked by Wall St. Rank hold PRTK as of Q2 2018.

  • Omni Partners reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Omni Partners sold 154,564 Paratek Pharmaceuticals, Inc. shares in Q2 2018, an estimated $2.01M.
  • Omni Partners first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2017 and held it in 2 quarters.
  • Omni Partners's Paratek Pharmaceuticals, Inc. position peaked at $3.71M in Q3 2017.
  • 110 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2018.

Based on Omni Partners's 13F filing for Q2 2018, filed 15 Aug 2018.